A brief history of the development of methods of organ storage with special emphasis on liver storage is presented. The current status of experimental liver storage is reviewed, emphasizing that hypothermia is at present the principal protective factor in all successful methods of liver storage.

organs in vitro, are using one or more of the following modalities: hypothermia, hyperbaria, metabolic inhibitors and continuous or intermittent perfusion.

**HISTORY**

**Hypothermia**

John Hunter was probably the first to use hypothermia for purposes of tissue storage. In 1766 he froze 2 carp in ordinary river water in an attempt to keep fish 'alive' in a frozen state. Hunter thought that such an experiment could produce a stepping-stone to the prolongation of life. Fuhrman and Field demonstrated that the physiological basis for its use was an exponential fall in oxygen uptake by the tissue associated with a fall in the core temperature. Subzero temperatures should theoretically provide the optimum reduction in metabolism, but the biological effects incurred during freezing preclude successful whole organ preservation at temperatures below 0°C.

**Hyperbaria**

The mode of action of hyperbaric oxygen in extending in vitro preservation beyond that achieved with hypothermia alone has not been defined. Bloch et al. showed that oxygen, under given conditions of temperature, can diffuse passively into heart muscle, but doubt has been expressed whether oxygen, under the same conditions, can pass through Glisson's capsule in the liver or the renal capsule. An alternate explanation to its mode of action is the inhibition of oxidation by virtue of its toxic effect on cell metabolism, although Lyons et al. feel that it is unlikely that oxygen poisoning occurs during the period of in vitro storage. Preservation with inert gases under hyperbaric conditions has shown that hyperbaric helium and nitrogen are comparable to hyperbaric oxygen in heart and kidney preservation. Hence hyperbaria may exert its beneficial effect not by meeting the nutritional requirements of the organ nor by further inhibiting oxidative metabolism, but by preventing tissue oedema during hypothermic storage.

**Pharmacological Metabolic Inhibition**

A reversible drug-induced inhibition of metabolism should prolong tolerance to ischaemic injury in the same way as hypothermia, but with the advantage that drugs could be administered before the moment of death with the hope of protecting the organ not only after death, but principally during agonal deterioration and before other organ-preserving measures can be instituted. Numerous pharmacological agents have been described which have either a cell-stabilizing action or a general inhibitory effect on cellular metabolism. These include steroids, magnesium, phenoxybenzamine and phenothiazines. It is clear, however, that no drug yet described is dramatically useful by itself, and that such agents may be useful in combination with more effective methods to enhance the quality of the preserved organ.

**Perfusion**

In 1812 Le Gallois expressed his belief in the feasibility of artificially maintaining an organ indefinitely by substituting the heart with a perfusion system. A century later, Hooker took the concept of perfusion to its ultimate refinement by introducing a system which could both aerate the blood and pump it at a variable pulse pressure through an organ with a vascular pedicle. With the current surge of interest in organ transplantation, and the success achieved in perfusion storage of kidneys, both experimentally and clinically, perfusion storage of the liver as a method of preservation preceding transplantation is currently being extensively investigated.

Continuous perfusion should ideally fulfill the same purpose as the circulation of blood through the body, namely the continuous and adequate supply of oxygen and nutrients and the continuous removal of carbon dioxide and other end-products of metabolism. The factors which determine successful perfusion were set down by Carrel and Lindbergh. They more than adequately describe the technical and mechanical problems involved in an artificially produced perfusion system. Numerous tests have been described to assess liver function in the isolated state. However, the only true test of successful storage is the ability of the organ to support life in a hepatectomized animal.

**PRESENT STATUS OF SUCCESSFUL EXPERIMENTAL LIVER STORAGE**

Hepatic hypothermia produced by the introduction of cold electrolyte solution into the portal vein will preserve the function of a canine liver for 2 hours. Using a preserving solution of homologous plasma with added bicarbonate and dextrose, this period can be extended to 3-5 hours. Recently, we reported successful hypothermic immersion storage for up to 8 hours in the pig. Nine of 10 animals survived longer than 5 days; the longest-surviving animal is still alive 350 days after the transplant.

The addition of hyperbaric oxygen to hypothermic storage of the liver has not been well studied. Brettschneider et al. preserved 3 canine livers for 24 hours at 4°C and 40 psig. Two recipients failed to survive the operation and a third died before the 4th postoperative day. When perfusion with diluted blood via the portal vein and hepatic artery was added to this system canine livers could be preserved for 8-9½ hours with good early function.

Belzer et al. using perfusion without hyperbaric oxygen, successfully stored pig livers for 8-10 hours and concluded that damage to the endothelium of the liver sinusoids when perfusing beyond this period precluded a successful result.
The experimental data serve to confirm that hypothermia is at present the principal protective factor in all currently successful methods of liver storage. Its use is simple and the result is comparable to that obtained with complicated techniques. It should furthermore provide a more practical application in the procurement and short-term preservation of liver grafts for clinical hepatic transplantation. The addition of hyperbaria, pharmacological agents and even perfusion may prolong the period of preservation by a few hours, but will not provide the answer to long-term storage of the liver.

The experimental work referred to was supported in the University of Cape Town by the Medical Research Council, the C. L. Herman Bequest and the Cape Provincial Administration.

REFERENCES

The Antistreptolysin Titre (ASO Titre) as a Diagnostic Index in Hepatitis

N. GITLIN, M.B., CH.B., M.R.C.P. (LOND.), M.R.C.P. (EDIN.) and I. R. DOWDESWELL, M.B., CH.B., Liver Clinic, Groote Schuur Hospital and Department of Medicine and Liver Research Group, University of Cape Town, O. L. MEYERS, M.B., CH.B., F.C.P. (S.A.), Immunology Laboratory, Department of Medicine, University of Cape Town, and A. A. FORDER, M.B., CH.B., M.MED. (PATH.), Department of Pathology, University of Cape Town

SUMMARY
A series of patients suffering from hepatitis and jaundice were studied in order to ascertain whether the ASO titre would assist in early diagnosis of these diseases, and whether it would help in the differentiation of the various types of hepatitis.


At present there is no simple single investigation that is specific for the diagnosis of viral hepatitis. The discovery of the Australia antigen (hepatitis-associated antigen) was heralded as the answer to this problem; however, with time it has been shown that the Australia antigen is not present in a considerable percentage of patients with viral hepatitis. 1, 2, 3, 4 Consensus of opinion now favours that it is only present in patients with serum hepatitis and then in only about 40% - 60% of patients depending on the stage of the illness, frequency of testing and technique applied. 1, 2, 3, 4, 5 Also, the Australia antigen may not be specific for viral hepatitis as it also detected in patients with chronic aggressive hepatitis and hepatoma of the liver. 1, 2, 3, 4, 5

The German and Swedish workers have reported that the antistreptolysin titre (ASO titre) was elevated in acute